Please login to the form below

Not currently logged in
Email:
Password:

ProStrakan lines up new chairman for 2014

Dr John Brown will replace Peter Allen

ProStrakan Dr John BrownProStrakan's chairman Peter Allen has resigned from the company and will step down from the UK specialty pharmaceutical company's board at the end of the year.

He will be replaced by Dr John Brown, who is currently chairman of the government-backed Cell Therapy Catapult and Scottish contract research organisation CXR Biosciences.

Dr Brown also co-chairs the Scottish Government's Life Science Industry Advisory Board and was formerly chairman of BTG, Axis-Shield and, prior to that, chief executive of Acambis.

His appointment takes effect on January 1, 2014 after the departures of Peter Allen and non-executive Dr Michael Asbury, moves that ProStrakan said follow its own successful integration into its Japanese parent company Kyowa Hakko Kirin.

ProStrakan's chief executive Dr Tom Stratford said: "Peter and Mike have each been long-standing members of the ProStrakan board and, during their time with us, ProStrakan has grown significantly and transitioned from being a small independent company into an important part of Kyowa Hakko Kirin."

He added: "We are thrilled to have been able to attract someone with John's credentials as our new chairman. John brings with him a wealth of experience of the life sciences industry and we look forward to the guidance and advice that he will undoubtedly bring to the ProStrakan board.”

13th November 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics